Gilead Sciences (GIS) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Gilead Sciences DE:GIS is currently developing the following drugs: Gs-3242, B/F/Taf, Lenacapavir, Len, Lenacapavir Injection, Lenacapavir Tablet, B/F/Taf, Gs-3242 Tablet, Gs-3242 Injection, Len, Gs-1206, Lenacapavir Tablet, Cabotegravir, Lenacapavir, Teropavimab, Zinlirvimab, Rilpivirine, Cab, Rpv, Len, Lenacapavir Tablet, Lenacapavir, Teropavimab, Zinlirvimab, Sbr, Len, Gs-2426, Paclitaxel, Ramucirumab, Nivolumab, Denikitug, Bevacizumab, Nivolumab, Denikitug, Trifluridine-Tipiracil, Gs-5319, Standard Of Care, Bvy, Gs-1219, Gs-4321, B/F/Taf, Lenacapavir Injection, Lenacapavir Tablet, Standard Of Care, Gs-3242, Bvy, Filgotinib Maleate, Sacituzumab Govitecan-Hziy, Gs-0151, Topotecan, Sacituzumab Govitecan, Amrubicin, Obeldesivir, Zimberelimab, Com503, Oral Lenacapavir, Subcutaneous Lenacapavir, Optimized Background Regimen, Carboplatin, Paclitaxel, Zimberelimab, Domvanalimab, B/F/Taf, Isl/Len, Ptm B/F/Taf, Ptm Isl/Len, Isl/Len, Antiretroviral Combinations, Gs-1720, Gs-4182, Bictegravir/Emtricitabine/Tenofovir Alafenamide, Gs-1720/Gs-4182 Fdc, Omeprazole, Gs-4571, Zimberelimab, Gs-2121, Lenacapavir, Bic/Len Fdc, Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/Tenofovir Disoproxil Fumarate, Paclitaxel, Doxorubicin, Sacituzumab Govitecan-Hziy, Atv, Drv, E/C/F/Taf, 3Rd Arv Agent, B/F/Taf, F/Taf, Cobicistat, NucleosIde Reverse Transcriptase Inhibitors, Lopinavir Boosted With Ritonavir, Bictegravir, B/F/Taf, Lenacapavir, Gs-1427, Sacituzumab Govitecan, Gs-0201. These drug candidates are in various stages of clinical development as the company works toward FDA approval.